NewAmsterdam Pharma Company N.V.
Leadership moves, last update 4 weeks ago
Pharma biotech · Headquarters Netherlands
Everything we hold on NewAmsterdam Pharma Company N.V., newest first. Every line links to the filing or report it came from.
- 2026-07-22Headcount Not Stated Leadership moves
NewAmsterdam Pharma Co N.V. 8-K filing (Item 5.02): officer or director change
NewAmsterdam Pharma's COO steps down in August to lead another biotech firm; the company plans transition services for its clinical programs.
- 2026-06-03Headcount Not Stated Leadership moves
NewAmsterdam Pharma Co N.V. 8-K filing: officer or director change
NewAmsterdam Pharma's shareholders approved an employee stock purchase plan, offering eligible employees a property interest in the company.
- 2026-04-24Headcount Not Stated Leadership moves
NewAmsterdam Pharma Co N.V. 8-K filing: officer or director change
Louise Kooij will leave her role as Chief Accounting Officer at NewAmsterdam Pharma in Naarden, The Netherlands, with a separation agreement in place.
- 2025-12-31Pay Change Pay and benefits
NewAmsterdam Pharma Company N.V.: $13,641,854 total compensation for the principal executive officer, fiscal year ended 2025-12-31
Top-of-house pay is the anchor the rest of an employer's pay structure is set against, and it is the one compensation figure every US-listed company must publish on the same basis. Read it as a comparable, not as a salary band: it is a single officer's total, including equity awards valued under SEC rules, and it says nothing directly about what a given role pays.
- 2024-12-31Pay Change Pay and benefits
NewAmsterdam Pharma Company N.V.: $6,469,297 total compensation for the principal executive officer, fiscal year ended 2024-12-31
Top-of-house pay is the anchor the rest of an employer's pay structure is set against, and it is the one compensation figure every US-listed company must publish on the same basis. Read it as a comparable, not as a salary band: it is a single officer's total, including equity awards valued under SEC rules, and it says nothing directly about what a given role pays.
- 2023-12-31Pay Change Pay and benefits
NewAmsterdam Pharma Company N.V.: $5,805,558 total compensation for the principal executive officer, fiscal year ended 2023-12-31
Top-of-house pay is the anchor the rest of an employer's pay structure is set against, and it is the one compensation figure every US-listed company must publish on the same basis. Read it as a comparable, not as a salary band: it is a single officer's total, including equity awards valued under SEC rules, and it says nothing directly about what a given role pays.
The read-through on each line is our interpretation. The headline and figures come from the linked source. Data licensed CC BY 4.0. Back to the tracker